AU2023201404A1 — Modulators of cystic fibrosis transmembrane conductance regulator
Assigned to Vertex Pharmaceuticals Inc · Expires 2023-04-06 · 3y expired
What this patent protects
The present invention features a compound of formula I: W z~ A B (R2)p (Y). C (R3)q I, or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. Th…
USPTO Abstract
The present invention features a compound of formula I: W z~ A B (R2)p (Y). C (R3)q I, or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof. 1475
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.